Director Eugene Williams of ProMIS Neurosciences Inc. filed a Form 4 on November 6, 2026, disclosing a purchase of 26,500 common shares on November 4, 2026.

Key Highlights

  • Reporting person: Eugene Williams, director of ProMIS Neurosciences Inc. (NASDAQ:PMN)
  • Transaction: Purchase (transaction code P) of 26,500 common shares on November 4, 2026
  • Price per share: $3.43
  • Beneficial ownership following transaction: 40,213 common shares held directly
  • No derivative securities were reported as acquired, disposed of, or beneficially owned
  • Filing signed by Max A. Milbury as attorney-in-fact for Eugene Williams on November 6, 2026

ProMIS Neurosciences Director Williams Reports Open-Market Common Share Purchase

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Eugene Williams, a director of ProMIS Neurosciences Inc. (NASDAQ:PMN), acquired 26,500 common shares on November 4, 2026, at a price of $3.43 per share. The transaction is coded "P," indicating an open-market purchase. The filing reports that Williams now directly holds 40,213 common shares following the transaction.

The filing was submitted on November 6, 2026, and was signed by Max A. Milbury as attorney-in-fact for Eugene Williams. No derivative securities, such as options or warrants, were reported in Table II of the form. The form indicates the filing was made by one reporting person, and there is no indication of an amendment to a prior filing.

The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox was not checked. ProMIS Neurosciences Inc. is listed on NASDAQ under the ticker symbol PMN, and the company's address of record for the reporting person is Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada.

What Was Disclosed

Director Eugene Williams reported the direct purchase of 26,500 ProMIS Neurosciences common shares at $3.43 each on November 4, 2026, bringing his total direct beneficial ownership to 40,213 shares, according to the Form 4 filed November 6, 2026.